Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
(Stockholm 18 July 2022) A US company with an extensive pipeline in medical dermatology has chosen Inhalation Research Services (IRS), ISAB's contract research organization, for a research project worth 1.45 million SEK (1.36 K Euro) into a new repurposed drug that is being reformulated for administration via the lungs. ISAB's world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) solution, were decisive in the client's choice.
The new US client has chosen ISAB's ex vivo IPL (Isolated Perfused Lung) solution to test its new repurposed drug that is being reformulated for administration via the lungs. ISAB's version of IPL is a highly lung-specific methodology that is specially tailored for aerosols generated by its PreciseInhale[®] system. It bypasses any potential delivery issues with in vivo exposures and will deliver high-precision (Standard Derivation is typically below 10%) and high-resolution PK data.
Both dermatology and the repurposing of drugs are high-growth areas within the pharmaceutical industry. The reduced development time and costs of repurposing drugs to treat new indications has led to significant market growth and an increase in the number of research projects.
ISAB CEO Manoush Masarrat: "as we stated earlier this year, we have intensified our efforts within Inhalation Research Services. We are pleased to start this fascinating project with a new customer from the US, one of our key markets. We look forward to delivering them high-value knowledge and data that will help reduce risk and accelerate development right from the very start of their project."